Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SDHB | P21912 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676939 | 1.00 | PPARA (0.40) | PPARAPPARGEGFRPPARDERBB2 | |
| SCHEMBL1676509 | 0.92 | KIF11 (0.43) | PPARAEGFRERBB2CNR1CNR2 | |
| SCHEMBL1676510 | 0.92 | KIF11 (0.43) | PPARAEGFRERBB2CNR1CNR2 | |
| SCHEMBL1676486 | 0.91 | PPARG (0.38) | PPARAPPARGEGFRERBB2DPP4 | |
| SCHEMBL1676245 | 0.85 | GCGR (0.39) | PPARAPPARGEGFRPPARDERBB2 | |
| SCHEMBL1676243 | 0.85 | GCGR (0.39) | PPARAPPARGEGFRPPARDERBB2 | |
| SCHEMBL1676691 | 0.84 | PLAU (0.35) | PPARAPPARGEGFRERBB2DPP4 | |
| SCHEMBL1676649 | 0.84 | PTPN1 (0.40) | PPARAPPARGCNR1 | |
| SCHEMBL1676053 | 0.84 | PTPN1 (0.40) | PPARAPPARGCNR1 | |
| SCHEMBL1483842 | 0.84 | PPARA (0.38) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | PPARA 2606/4885PPARG 2054/4885EGFR 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.